Do GLP-1 Agonists increase risk of thyroid cancer? A recent article from France noted increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 Receptor Agonists (medications like Ozempic, Wegovy, Mounjaro, Trulicity, Victoza). I break down the study and discuss risks vs benefits.

Dr Kim is a physician, board-certified in Internal and Obesity Medicine, with a passion for preventive health, weight loss, metabolic health, and longevity.

DISCLAIMER:
This video is for general information and educational purposes only and does NOT constitute the practice of medicine or other professional health services, including giving of a medical advice. No doctor-patient relationship is formed. The use of this information and the materials provided in the video is at user’s own risk. The contents of the video are not intended to be a substitute for professional medical advice and are not intended to treat, diagnose, cure or prevent disease. Viewers should not delay or disregard obtaining medical advice for any medical condition they have and seek the assistance of their healthcare professionals for any such conditions. Leonid Kim will not assume any liability for any direct or indirect losses or damages that may result from use of the information contained in this video, including but not limited to, economic loss, injury, illness, or death. Furthermore, all content in the video is subject to change without notice, so the content creator assumes no responsibility for the accuracy of information contained. Please review all information regarding any medical condition or use of medications and/or supplements with your physician or healthcare provider.

The contents of this video are my personal opinion and do not represent that of my employer(s).